CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: CCR4 is a validated therapeutic target in TCL: mogamulizumab, a humanized, defucosylated anti-CCR4 monoclonal antibody (KW-0761) has received FDA approval for the treatment of r/r CTCL [181,182,183,184].